Transfusion and Apheresis Science, Год журнала: 2025, Номер unknown, С. 104171 - 104171
Опубликована: Июнь 1, 2025
Язык: Английский
Bone Marrow Transplantation, Год журнала: 2022, Номер 57(8), С. 1217 - 1239
Опубликована: Май 19, 2022
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based clinical and scientific developments in field. This is eighth special report HCT haematological diseases, solid tumours immune disorders. Our aim to provide general guidance according prevailing countries centres. In order inform patient decisions, these must be considered conjunction with risk of disease, procedure non-transplant strategies, including evolving cellular therapies. techniques are constantly we make no specific recommendations, but encourage harmonisation practice, where possible, ensure experience across can meaningfully aggregated via registry outputs. We also recommend working JACIE accreditation standards maintain quality laboratory components benchmarking survival outcomes. Since last edition, COVID-19 pandemic affected decision making activity indications. Although full impact yet determined, that delivered ongoing reference national guidance, accordance current local conditions.
Язык: Английский
Процитировано
265
Nature Reviews Disease Primers, Год журнала: 2023, Номер 9(1)
Опубликована: Июнь 8, 2023
Язык: Английский
Процитировано
117
Bone Marrow Transplantation, Год журнала: 2023, Номер 58(6), С. 647 - 658
Опубликована: Март 6, 2023
Abstract In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 received advanced cellular therapies, 2524 of which CAR-T treatments, an additional 3245 DLI. Changes compared to the previous year treatment (+35%), +5.4%, autologous +3.9%, more pronounced non-malignant disorders. Main indications for myeloid malignancies 10,745 (58%), lymphoid 5127 (28%) disorders 2501 (13%). 22,129 (90%) solid tumors 1635 (7%). HCT, use haploidentical donors decreased −0.9% while unrelated sibling increased +4.3% +9%. Cord blood −5.8%. Pediatric overall +5.6% (+6.9% +1.6% autologous). Increase was mainly restricted high-income countries. The drop activity 2020 partially recovered second SARS-CoV-2 pandemic. transplant community confronted with pandemic challenge, continued providing access treatment. This annual EBMT report reflects current activities useful health care resource planning.
Язык: Английский
Процитировано
63
Blood, Год журнала: 2024, Номер 143(19), С. 1903 - 1930
Опубликована: Фев. 2, 2024
Abstract Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need guidance regarding management of (ALL) diagnosis to aftercare. The has previously summarized their recommendations diagnostic approaches, prognostic factors, and assessment ALL. current recommendation summarizes clinical management. It covers treatment including use new immunotherapies, application minimal residual disease decisions, specific subgroups, challenging situations as well late effects supportive care. provides physicians caring patients with ALL which be complemented by regional expertise preferably provided national academic study groups.
Язык: Английский
Процитировано
40
Bone Marrow Transplantation, Год журнала: 2024, Номер 59(6), С. 803 - 812
Опубликована: Март 4, 2024
Abstract In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 received advanced cellular therapies, 3205 of which CAR-T. An additional 2854 DLI. Changes compared to the previous year an increase CAR-T treatments (+27%) decrease (−4.0%) autologous (−1.7%). Main indications for myeloid malignancies (10,433; 58.4%), lymphoid (4,674; 26.2%) non-malignant disorders (2572; 14.4%). lymphomas (7897; 32.9%), PCD (13,694; 57.1%) solid tumors (1593; 6.6%). HCT, use sibling donors decreased −7.7%, haploidentical −6.3% unrelated −0.9%. Overall cord blood −16.0%. Use allogeneic, a lesser degree likely reflecting availability new treatment modalities, including small molecules, bispecific antibodies, cells. Pediatric activity remains stable (+0.3%) with differences between HCT. continues reached cumulative total 9039 treated wide across countries. After many years continuous growth, application seems have slowed down.
Язык: Английский
Процитировано
39
Bone Marrow Transplantation, Год журнала: 2025, Номер unknown
Опубликована: Фев. 12, 2025
Язык: Английский
Процитировано
4
Blood Cancer Journal, Год журнала: 2024, Номер 14(1)
Опубликована: Июль 5, 2024
Abstract Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles challenged by CAR-T-cells other immunotherapies. We examined the trends outcomes DLBCL patients undergoing auto-/allo-HSCT between 1990 2021 reported to EBMT. Over this period, 41,148 underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 2018. The recent decline transplants corresponds increased CAR-T (1117 2021). Median age auto-HSCT rose from 42 (1990–1994) 58 years (2015–2021), with peripheral blood becoming primary source post-1994. Allo-HSCT median 36 54 (2015–2021) years, mobilized as post-1998 reduced intensity conditioning post-2000. Unrelated mismatched accounted 50% 19% 2015–2021. Three-year overall survival (OS) after improved 56% 70% p < 0.001, decrease relapse incidence (RI) 49% 38%, non-relapse mortality (NRM) remained unchanged (4%). After allo-HSCT, 3-year-OS 33% (1990–1999) 46% ( 0.001); 3-year RI 39% 1-year-NRM decreased 0.001). Our data reflect advancements over 32 >40,000 transplants, providing insights evaluating emerging therapies.
Язык: Английский
Процитировано
8
Chinese Medical Journal, Год журнала: 2022, Номер 135(12), С. 1394 - 1403
Опубликована: Июнь 20, 2022
Abstract Hematopoietic stem cell transplantation (HSCT) is a highly effective and unique medical procedure for the treatment of most hematological malignancies. The first allogeneic was performed by E. Donnall Thomas in 1957. Since then, field has evolved expanded worldwide. successful allogenic HSCT (allo-HSCT) China conducted 1981. Although development allo-HSCT lagged, since made considerable contributions to process worldwide, with more than 10,000 HSCTs annually. In particular, haploid (haplo-HSCT) technology represented Beijing Protocol demonstrated similar efficacy human leukocyte antigen-matched gradually become pre-dominant choice China. Currently, number haplo-HSCT procedures exceeds 5000 per year, been greatly improved implementing updated individualized strategies controlling complications, relapse, infection management. addition, innovative technologies developed different centers, such as Soochow, Zhejiang, Fujian, Chongqing, Anhui, have emerged, providing inspiration refinement global practice. This review will focus on current activity this highlight important trends that are vital China's process, examining viewpoint future directions.
Язык: Английский
Процитировано
29
Transplantation and Cellular Therapy, Год журнала: 2022, Номер 28(12), С. 810 - 821
Опубликована: Сен. 11, 2022
This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult pediatric HCT cellular therapy patients. was prepared using available data with expert opinion provided members (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) an update pervious publication. Since our original publication 2020, NIH IDSA have published extensive guidelines COVID-19 which are readily accessible ( Guidelines , ). focuses primarily on issues pertaining specifically to HCT/cellular recipients. Information this manuscript may change new information becomes available.
Язык: Английский
Процитировано
25
Best Practice & Research Clinical Haematology, Год журнала: 2024, Номер 37(2), С. 101561 - 101561
Опубликована: Июнь 1, 2024
Язык: Английский
Процитировано
6